Exclusive: Kevin Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S.
The former OpenAI executive's new lab startup told RuntimeWire it wants to "partner broadly with the frontier labs." Its own site lists OpenAI and Anthropic leaders among its angels.
By Morgan Laning · Published
Why it matters
Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S. for commercial, intellectual-property and geopolitical reasons.
Warp Sciences, the drug-chemistry startup Kevin Weil launched on Thursday, says the first companies lining up to use it are interested in moving their discovery work back to the U.S.
"Our early customers are interested in moving their drug discovery work back to the US for commercial, IP, and geopolitical reasons," Weil, Warp's CEO, told RuntimeWire in an email on Thursday, hours after the company came out of stealth.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.